Clinical reference Biomarker Directory
Back to directory

Factor B Complement Antigen

Emerging

Factor B abnormalities drive alternative complement pathway overactivation in aHUS and C3 glomerulopathy.

Also known as Factor B complement factor B CFB
In plain language

Factor B is part of a different branch of the complement immune defense system than the components discussed earlier. Genetic problems with it can cause a serious kidney disease, now treatable with drugs that block a related complement protein further downstream.

Biomarker & context

Complement Factor B is a key protein of the alternative complement pathway, distinct from the classical pathway components (C1q, C2, C4) discussed elsewhere in this biomarker set.

What it indicates

Abnormalities in Factor B are implicated in atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy, both conditions of uncontrolled alternative pathway activation causing kidney damage.

Diagnosis & clinical testing

Genetic Factor B variants are tested for as part of the broader complement gene panel used to evaluate aHUS and C3 glomerulopathy, alongside genes like CFH (complement factor H) and CFI (complement factor I), since identifying the specific genetic driver informs prognosis and treatment approach.

Guiding treatment

Confirmed complement-mediated aHUS is treated with eculizumab or ravulizumab (complement C5 inhibitors, connecting to the C5 complement discussion earlier in this biomarker set), which have transformed outcomes in this previously often-fatal condition.

Clinical significance

Connects to the earlier C5 complement discussion, since aHUS is now treated with C5-blocking drugs (eculizumab, ravulizumab).

References
  1. General nephrology reference literature on complement Factor B in atypical hemolytic uremic syndrome and C3 glomerulopathy.